VNRX
AMEXVolitionRX Limited
News · 26 weeks51-77%
2026-04-192026-10-11
Mix2790d
- SEC Filings16(59%)
- Other7(26%)
- Earnings2(7%)
- Insider2(7%)
Latest news
25 items- INSIDERChief Commercial Officer Forterre Gael covered exercise/tax liability with 284 shares, decreasing direct ownership by 2% to 16,284 units (SEC Form 4) (tax liability)4 - VOLITIONRX LTD (0000093314) (Issuer)
- INSIDERChief Operating Officer Michel Gaetan covered exercise/tax liability with 608 shares, decreasing direct ownership by 5% to 12,232 units (SEC Form 4) to cover withholding tax4 - VOLITIONRX LTD (0000093314) (Issuer)
- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in FranceHENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) (NYSE:VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis. DETECSEPS aligns with Volition's core purpose – to revolutionize the diagnosis and monitoring of life-altering diseases such as sepsis. Sepsis is a dysregulated response of the body to an infection, responsible for the failure of one or more organs and which can quickly become life-threatening. Worldwide, it is estimated that this p
- PRVolitionRx Participates in Launch of DETECSEPS Program in FranceFrench Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of SepsisHENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) (NYSE:VNRX, NYSE:VNRX) (together with affiliates, "Volition"), a multi-national epigenetics company, today announces, as part of the DETECSEPS Consortium, the official launch of the DETECSEPS project on the early detection of sepsis. The Consortium is funded with €6.3 million (~$7.3 million) from the French government. DETECSEPS is an initiative of IHU SEPSIS – the world'
- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027Reduces Equity OverhangHENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment, all obligations under the Note have been satisfied. The senior secured convertible promissory note, dated January 7, 2026, in the original principal amount of $2,400,000, also issued to Lind, remains outstanding in the amount of $2,041,667. Cameron Reynolds,
- SECSEC Form EFFECT filed by VolitionRX LimitedEFFECT - VOLITIONRX LTD (0000093314) (Filer)
- PRVolition Presents Early Stage I Solid Cancer Detection at the ESMO MAP ConferenceTargets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev., Sept. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage I solid cancer. Dr Andrew Retter, Medical Consultant, Volition, said:"We were delighted to be selected
- SECAmendment: SEC Form S-3/A filed by VolitionRX LimitedS-3/A - VOLITIONRX LTD (0000093314) (Filer)
- SECAmendment: SEC Form S-3/A filed by VolitionRX LimitedS-3/A - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form S-3 filed by VolitionRX LimitedS-3 - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form S-8 filed by VolitionRX LimitedS-8 - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form 10-Q filed by VolitionRX Limited10-Q - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Limited Announces Second Quarter 2026 Financial Results and Business UpdateConference call to discuss financial and operational results scheduled forFriday, August 14 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., Aug. 13, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter of 2026. Volition management will host a conference call tomorrow, August 14 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We have made strong progress across all of our product pillars throughout 2026 to date."W
- PRVolition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis PatientsRemoves Centralized Lab Dependency for $3.8 Billion Global Addressable Market forNETosis TestingHENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing. This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients in the ER or at the bedside, thereby greatly expanding the potential market beyond centralized lab testing. It also has
- PRVolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business UpdateConference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., Aug. 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter 2026 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Second Quarter 2026 Earnings and Business Update Conference Call Date: Friday, August 14, 2026Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)
- SECVolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy TechnologyTargets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.HENDERSON, Nev., Aug. 5, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition today announces the publication of the first peer-reviewed paper describing the technology in detail - entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1". Most current liquid bi
- PRVolition Advances Nu.Q® NETs Platform Towards CommercializationConsistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable marketHENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product. It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings. Mr. Gael Forterre, Chief Commercial Officer, Volition commented:"We are in active di
VNRX FAQ
7 questionsWhat does VolitionRX Limited do?
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.Where does VNRX stock trade?
VolitionRX Limited (VNRX) is listed on AMEX.What sector and industry is VNRX in?
VolitionRX Limited operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did VolitionRX Limited go public?
VolitionRX Limited (VNRX) completed its IPO in 2015.What are analysts saying about VNRX?
VolitionRX Limited has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $250.00 price target on 2025-04-08. Recent price targets range from $250.00 to $900.00.What companies are similar to VNRX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation). Compare VNRX side-by-side with any of them on Quantisnow.How can I track VNRX on Quantisnow?
Quantisnow aggregates VolitionRX Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VNRX to receive live email and push alerts on every new disclosure.